Anti-LIV-1/SLC39A6 Antibody (LadiratuzumAb)
Catalog No.
F1510
Anti-LIV-1/SLC39A6 Antibody (LadiratuzumAb)
Featured Products
Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against LIV-1/ZIP6. Ladiratuzumab is conjugated with the microtubule disruptor MMAE to synthesize an antibody-active molecule conjugate (ADC) SGN-LIV1A. Ladiratuzumab can be used in breast cancer research.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
146.96 kDa
Dry ice
1629760-28-6
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
HLIV22
100 mM Pro 20 mM Arg pH 5.0. No preservative!
Q13433
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
Human LIV-1 CHO Cell Line were stained with ladiratuzumab and negative control protein respectively, washed and then followed by PE and analyzed with FACS
LIV-1 / SLC39A6
Please avoid freeze-thaw cycles.